Stay updated on BGB324 in Recurrent Glioblastoma Surgery Clinical Trial
Sign up to get notified when there's something new on the BGB324 in Recurrent Glioblastoma Surgery Clinical Trial page.

Latest updates to the BGB324 in Recurrent Glioblastoma Surgery Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check64 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check78 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a phase I trial for the AXL inhibitor BGB324 in treating recurrent glioblastoma, while adding new identifiers and collaborators related to the study.SummaryDifference44%
- Check85 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to BGB324 in Recurrent Glioblastoma Surgery Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BGB324 in Recurrent Glioblastoma Surgery Clinical Trial page.